Biomind Labs Inc

NEO:BMND

Biomind Labs, Inc. operates as a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-07-27. The firm is primary engaged as a biotech platform, which integrates biology, chemistry, medicine, neuroscience, technology, intellectual property and pharma grade production. Through its platform, the Company is engaged in the development of pharmaceutical formulations of the main psychedelic molecules, DMT, 5-MeO-DMT (2-(5-Methoxy-1H-indol-3-yl)-N, N-dimethyltryptamine) and mescaline 2-(3,4,5-trimethoxyphenyl)-ethylamine for treating a range of therapeutic indications. 5-MeO-DMT is a psychotropicbiomolecule from the tryptamine class. 5-MeO-DMT is a potent agonist on 5-HT1A and 5-HT2A receptors. Ayahuasca is a psychoactive beverage that contains, as active ingredients, a complex mixture of alkaloids composed mainly by DMT and the β-carbolines harmine, harmaline and tetrahydroharmine. Mescaline is a phenylethylamine alkaloid structurally related to the neurotransmitter dopamine.